

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	27	AUG 13	CA/CAPplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	28	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	29	AUG 15	CAPplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:58:47 ON 22 AUG 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:59:16 ON 22 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 AUG 2008 HIGHEST RN 1042670-14-3  
DICTIONARY FILE UPDATES: 21 AUG 2008 HIGHEST RN 1042670-14-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> E "UDP-GALN"/CN 25  
E1            1      UDP-GALACTURONATE 4-EPIMERASE/CN  
E2            1      UDP-GALACTURONIC ACID/CN  
E3            0 --> UDP-GALN/CN  
E4            1      UDP-GALNAC TRANSFERASE T10 (HUMAN KHM-1B CELL GENE GALNT10)/CN  
E5            1      UDP-GALNAC-S/CN  
E6            1      UDP-GALNAC:B-GALACTOSIDE  
A1-4-N-ACETYL GALACTOSAMINYLTRANSFERASE (CAMPYLOBACTER JEJUNI)/CN  
E7            1      UDP-GALNAC:BETAGLCNAC BETA 1,3-GALACTOSAMINYLTRANSFERASE,  
POLYPEPTIDE 2 (XENOPUS TROPICALIS CLONE MGC:108126 IMAGE:7005588 GENE  
B3GALNT2-PROV)/CN  
E8            1      UDP-GALNAC:GLCNAC B1,4-N-ACETYL GALACTOSAMINYLTRANSFERASE  
(CAENORHABDITIS ELEGANS)/CN

E9 1 UDP-GALNAC:GLCNACB-R  
 B1.FWDARW.4-N-ACETYL GALACTOSAMINYLTRANSFERASE/CN  
 E10 1 UDP-GALNAC:GLUCURONIDE A1-4-N-ACETYL GALACTOSAMINYLTRANSFERASE/CN  
 E11 1 UDP-GALNAC:NEU5ACA2-3GALB-R  
 B1,4-N-ACETYL GALACTOSAMINYLTRANSFERASE/CN  
 E12 1 UDP-GALNAC:NEUACA2,3GALB-R B1,4-N-ACETYL GALACTOSAMINE  
 TRANSFERASE (MOUSE CLONE PCDM8-CT)/CN  
 E13 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINETRANSFERASE ENZYME  
 E.C. 2.4.1.41 (OX CLONE G/B PRECURSOR)/CN  
 E14 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYL TRANSFERASE (HUMAN  
 CELL LINE MKN45 CLONE 2782 GENE GALNAC-T2)/CN  
 E15 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYL TRANSFERASE (HUMAN  
 CELL LINE MKN45 GENE GALNAC-T1)/CN  
 E16 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYL TRANSFERASE  
 (SWINE)/CN  
 E17 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE/CN  
 E18 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE  
 (CAENORHABDITIS ELEGANS STRAIN N2 GENE GLY-3)/CN  
 E19 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE  
 (CAENORHABDITIS ELEGANS STRAIN N2 GENE GLY-4)/CN  
 E20 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE  
 (CAENORHABDITIS ELEGANS STRAIN N2 GENE GLY-5 ISOENZYME A)/CN  
 E21 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE  
 (CAENORHABDITIS ELEGANS STRAIN N2 GENE GLY-5 ISOENZYME B)/CN  
 E22 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE  
 (CAENORHABDITIS ELEGANS STRAIN N2 GENE GLY-5 ISOENZYME C)/CN  
 E23 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE  
 (CAENORHABDITIS ELEGANS STRAIN N2 GENE GLY-6 ISOENZYME A)/CN  
 E24 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE  
 (CAENORHABDITIS ELEGANS STRAIN N2 GENE GLY-6 ISOENZYME B)/CN  
 E25 1 UDP-GALNAC:POLYPEPTIDE N-ACETYL GALACTOSAMINYLTRANSFERASE  
 (CAENORHABDITIS ELEGANS STRAIN N2 GENE GLY-6 ISOENZYME C)/CN

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.46	0.67

STN INTERNATIONAL LOGOFF AT 08:00:09 ON 22 AUG 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the EPOLINE Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUIDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	27	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	28	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	29	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:01:15 ON 22 AUG 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:01:26 ON 22 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 AUG 2008 HIGHEST RN 1042670-14-3  
DICTIONARY FILE UPDATES: 21 AUG 2008 HIGHEST RN 1042670-14-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> E "UDP GALACTOSAMINE"/CN 25  
E1 1 UDP DISODIUM SALT/CN  
E2 1 UDP FUCOSE/CN  
E3 0 --> UDP GALACTOSAMINE/CN  
E4 2 UDP GALACTOSE 4-EPIMERASE (HUMAN LYMPHOBLAST GENE GALE)/CN  
E5 1 UDP GALACTOSE UA/CN  
E6 1 UDP GALACTOSE-1,2-DIACYLGLYCEROL GALACTOSYLTRANSFERASE/CN  
E7 1 UDP GALACTOSE-2'-DEHYDROGENASE/CN  
E8 1 UDP GALACTOSE-4-EPIMERASE (PACHYSOLEN TANNOPHILUS CLONE XIN 3-41 GENE PTGAL10)/CN  
E9 1 UDP GALACTOSE-COLLAGEN GALACTOSYLTRANSFERASE/CN  
E10 1 UDP GALACTOSE-N-ACYLSPHINGOSINE GALACTOSYLTRANSFERASE/CN  
E11 1 UDP GALACTOSE:B-D-GALACTOSYL-1,4-N-ACETYL-D-GLUCOSAMINIDE A(1,3)-GALACTOSYLTRANSFERASE/CN  
E12 1 UDP GALACTURONATE-POLYGALACTURONATE A-GALACTURONOSYLTRANSFERASE/CN  
E13 1 UDP GLUCOSAMINE N-ACYLTRANSFERASE (AGROBACTERIUM TUMEFACIENS STRAIN C58 GENE LPXD)/CN  
E14 1 UDP GLUCOSAMINE N-ACYLTRANSFERASE (BDELLOVIBRIO BACTERIOVORUS STRAIN HD100)/CN  
E15 1 UDP GLUCOSAMINE N-ACYLTRANSFERASE (BRADYRHIZOBIUM JAPONICUM STRAIN USDA110 GENE LPXD)/CN  
E16 1 UDP GLUCOSAMINE N-ACYLTRANSFERASE (CHLAMYDIA PNEUMONIAE GENE LPXD)/CN

E17 1 UDP GLUCOSAMINE N-ACYLTRANSFERASE (CHLAMYDIA PNEUMONIAE STRAIN J138 GENE LPXD)/CN  
 E18 1 UDP GLUCOSAMINE N-ACYLTRANSFERASE (LEPTOSPIRA INTERROGANS COPENHAGENI STRAIN FIOCRUZ L1-130)/CN  
 E19 1 UDP GLUCOSE 4-EPIMERASE (PASPALUM VAGINATUM CLONE PS UGE1)/CN  
 E20 1 UDP GLUCOSE 4-EPIMERASE (SINORHIZOBIUM MELILOTI STRAIN 1021 GENE EXOB/SMB20942)/CN  
 E21 1 UDP GLUCOSE EPIMERASE (NEISSERIA MENINGITIDIS STRAIN B1940 CLONE PMF32.35 GENE GALE)/CN  
 E22 1 UDP GLUCOSE EPIMERASE (PARTIAL) (FRANKIA ALNI STRAIN ACN14A)/CN  
 E23 1 UDP GLUCOSE PHOSPHORYLASE/CN  
 E24 1 UDP GLUCOSE PYROPHOSPHORYLASE (GRACILARIA GRACILIS GENE UGP)/CN  
 E25 1 UDP GLUCOSE PYROPHOSPHORYLASE (PIG GENE UGP2)/CN

=> E "UDP-GALACTOSAMINE"/CN 25

E1 1 UDP-GALACTOPYRANOSE MUTASE GLF (STREPTOCOCCUS PNEUMONIAE STRAIN TP 25/38, SP 65/81 GENE GLF)/CN  
 E2 1 UDP-GALACTOPYRANOSE MUTASE MPN278 (MYCOPLASMA PNEUMONIAE STRAIN M129 GENE YEFE)/CN  
 E3 1 --> UDP-GALACTOSAMINE/CN  
 E4 1 UDP-GALACTOSE/CN  
 E5 1 UDP-GALACTOSE B-N-ACETYLGLUCOSAMINE B1,3-GALACTOSYLTRANSFERASE (HUMAN)/CN  
 E6 1 UDP-GALACTOSE 4'-EPIMERASE (HUMAN FIBROBLAST GENE GALE)/CN  
 E7 1 UDP-GALACTOSE 4-EPIMERASE/CN  
 E8 1 UDP-GALACTOSE 4-EPIMERASE (ACIDITHIOBACILLUS FERROOXIDANS STRAIN ATCC-23270)/CN  
 E9 1 UDP-GALACTOSE 4-EPIMERASE (AGROBACTERIUM TUMEFACIENS STRAIN C58 GENE GALE)/CN  
 E10 1 UDP-GALACTOSE 4-EPIMERASE (ALCANIVORAX BORKUMENSIS STRAIN SK2 GENE GALE)/CN  
 E11 1 UDP-GALACTOSE 4-EPIMERASE (ARABIDOPSIS THALIANA CLONE RAFL06-72-G11 (R11497) GENE AT4G10960)/CN  
 E12 1 UDP-GALACTOSE 4-EPIMERASE (ARTHROBACTER AURESCENS STRAIN TC1)/CN  
 E13 3 UDP-GALACTOSE 4-EPIMERASE (BACTEROIDES FRAGILIS STRAIN YCH46)/CN  
 E14 1 UDP-GALACTOSE 4-EPIMERASE (BACTEROIDES THETAIOAOMICRON STRAIN VPI-5482 GENE BT2887)/CN  
 E15 1 UDP-GALACTOSE 4-EPIMERASE (BRADYRHIZOBIUM JAPONICUM STRAIN 61A101C GENE GALE)/CN  
 E16 1 UDP-GALACTOSE 4-EPIMERASE (BRADYRHIZOBIUM JAPONICUM STRAIN USDA110 GENE GALE)/CN  
 E17 1 UDP-GALACTOSE 4-EPIMERASE (BREVIBACTERIUM LACTOFERMENTUM GENE GALE)/CN  
 E18 1 UDP-GALACTOSE 4-EPIMERASE (CORYNEBACTERIUM EFFICIENS STRAIN YS-314)/CN  
 E19 1 UDP-GALACTOSE 4-EPIMERASE (ERWINIA AMYLOVORA STRAIN EA7/74 CLONE PEA200 GENE GALE) (EC 5.1.3.2)/CN  
 E20 1 UDP-GALACTOSE 4-EPIMERASE (ESCHERICHIA COLI O157:H7 STRAIN EDL933 GENE Z3206)/CN  
 E21 1 UDP-GALACTOSE 4-EPIMERASE (ESCHERICHIA COLI STRAIN O157:H7 GENE ECS2847)/CN  
 E22 1 UDP-GALACTOSE 4-EPIMERASE (FRANKIA ALNI STRAIN ACN14A GENE GALE)/CN  
 E23 1 UDP-GALACTOSE 4-EPIMERASE (FRANKIA ALNI STRAIN ACN14A)/CN  
 E24 1 UDP-GALACTOSE 4-EPIMERASE (GALE-LIKE) (ACINETOBACTER BAUMANNII STRAIN ATCC 17978)/CN  
 E25 1 UDP-GALACTOSE 4-EPIMERASE (GALE-LIKE) (ACINETOBACTER STRAIN ADP1)/CN

=> S E3

L1 1 UDP-GALACTOSAMINE/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.65 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 17479-06-0 REGISTRY

CN Uridine 5'-(trihydrogen diphosphate), P'-(2-amino-2-deoxy- $\alpha$ -D-galactopyranosyl) ester (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Galactopyranose, 2-amino-2-deoxy-, 1 $\rightarrow$ 5'-ester with uridine 5'-(trihydrogen pyrophosphate),  $\alpha$ -D- (8CI)

CN Uridine 5'-(trihydrogen pyrophosphate), mono(2-amino-2-deoxy- $\alpha$ -D-galactopyranosyl) ester (8CI)

OTHER NAMES:

CN UDP-D-galactosamine

CN UDP-galactosamine

CN Uridine diphosphate galactosamine

CN Uridine diphosphogalactosamine

FS STEREOSEARCH

MF C15 H25 N3 O16 P2

CI COM

LC STN Files: ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, MEDLINE, TOXCENTER, USPAT2, USPATFULL


(\*File contains numerically searchable property data)

DT.CA CAPLUS document type: Conference; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

38 REFERENCES IN FILE CA (1907 TO DATE)

38 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.07

8.28

FILE 'CAPLUS' ENTERED AT 08:02:31 ON 22 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Aug 2008 VOL 149 ISS 9  
FILE LAST UPDATED: 21 Aug 2008 (20080821/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l1

L2 38 L1

=> s l2 not py>2003

6143104 PY>2003

L3 22 L2 NOT PY>2003

=> s l2/biol

FIELD CODES CANNOT BE CHANGED HERE

You may have tried to apply a field code to a term that already has a field code. You can only add a field code to a term that has no field code appended to it.

=> s l1/biol

38 L1

7479609 BIOL/RL

L4 26 L1/BIOL

(L1 (L) BIOL/RL)

=> s l4 not py>2002

7171741 PY>2002

L5 15 L4 NOT PY>2002

=>

=>

Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.20

18.48

SESSION WILL BE HELD FOR 120 MINUTES



STN INTERNATIONAL SESSION SUSPENDED AT 08:07:11 ON 22 AUG 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 08:11:58 ON 22 AUG 2008  
FILE 'CAPLUS' ENTERED AT 08:11:58 ON 22 AUG 2008  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.20	18.48

=> d his

(FILE 'HOME' ENTERED AT 08:01:15 ON 22 AUG 2008)

FILE 'REGISTRY' ENTERED AT 08:01:26 ON 22 AUG 2008

E "UDP GALACTOSAMINE"/CN 25

E "UDP-GALACTOSAMINE"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 08:02:31 ON 22 AUG 2008

L2 38 S L1

L3 22 S L2 NOT PY>2003

L4 26 S L1/BIOL

L5 15 S L4 NOT PY>2002

=> d l1

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 17479-06-0 REGISTRY

ED Entered STN: 16 Nov 1984

CN Uridine 5'-(trihydrogen diphosphate), P'-(2-amino-2-deoxy- $\alpha$ -D-galactopyranosyl) ester (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Galactopyranose, 2-amino-2-deoxy-, 1 $\rightarrow$ 5'-ester with uridine 5'-(trihydrogen pyrophosphate),  $\alpha$ -D- (8CI)

CN Uridine 5'-(trihydrogen pyrophosphate), mono(2-amino-2-deoxy- $\alpha$ -D-galactopyranosyl) ester (8CI)

OTHER NAMES:

CN UDP-D-galactosamine

CN UDP-galactosamine

CN Uridine diphosphate galactosamine

CN Uridine diphosphogalactosamine

FS STEREOSEARCH


MF C15 H25 N3 O16 P2

CI COM

LC STN Files: ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, MEDLINE, TOXCENTER, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

38 REFERENCES IN FILE CA (1907 TO DATE)  
38 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 08:01:15 ON 22 AUG 2008)

FILE 'REGISTRY' ENTERED AT 08:01:26 ON 22 AUG 2008

E "UDP GALACTOSAMINE"/CN 25

E "UDP-GALACTOSAMINE"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 08:02:31 ON 22 AUG 2008

L2 38 S L1

L3 22 S L2 NOT PY>2003

L4 26 S L1/BIOL

L5 15 S L4 NOT PY>2002

FILE 'REGISTRY' ENTERED AT 08:12:22 ON 22 AUG 2008

FILE 'CAPLUS' ENTERED AT 08:12:22 ON 22 AUG 2008

=> s 15 and (cancer? or tumor? or neoplas?)

389450 CANCER?

529345 TUMOR?

556783 NEOPLAS?

L6 3 L5 AND (CANCER? OR TUMOR? OR NEOPLAS?)

=> d ibib abs 1-3

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:144618 CAPLUS

DOCUMENT NUMBER: 118:144618

ORIGINAL REFERENCE NO.: 118:24807a,24810a


TITLE: Phosphorus metabolite characterization of human prostatic adenocarcinoma in a nude mouse model by phosphorus-32 magnetic resonance spectroscopy and high pressure liquid chromatography

AUTHOR(S): Kurhanewicz, John; Dahiya, Rajvir; Macdonald, Jeffrey M.; Jajodia, Prahalad; Chang, Lee Hong; James, Thomas L.; Narayan, Perinchery  
 CORPORATE SOURCE: Sch. Med., Univ. California, San Francisco, CA, 94143-0738, USA  
 SOURCE: NMR in Biomedicine (1992), 5(4), 185-92  
 CODEN: NMRBEF; ISSN: 0952-3480  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB A series of expts. were conducted to identify and quantify the phosphorus metabolites of DU 145 xenografts (a human prostatic adenocarcinoma cell line grown in nude mice) using  $^{31}\text{P}$  MRS and HPLC. The  $^{131}\text{P}$  spectral characteristics of DU 145 xenografts were compared to perfused DU 145 cells and to in situ human prostatic adenocarcinomas. These studies demonstrated that both DU 145 xenografts and perfused DU 145 cells exhibited reduced levels of phosphocreatine relative to spectra of in situ human prostatic adenocarcinomas. Elevated levels of phosphomonoesters (PMEs) were observed in  $^{31}\text{P}$  spectra of both DU 145 xenografts and in situ human prostatic adenocarcinomas. The major components of the PME resonance of DU 145 xenografts were identified as phosphocholine and phosphoethanolamine. High levels of diphosphodiester (DPDEs) were consistently observed for both DU 145 xenografts and perfused DU 145 cells, but were absent in  $^{31}\text{P}$  spectra of in situ primary human adenocarcinomas. In agreement with spectroscopic results, high pressure liquid chromatog. analyses of human tissue removed at surgery contained insignificant amts. of DPDEs while DU 145 xenografts had high levels of DPDEs consistently mainly of uridine-5'-diphospho-N-acetylgalactosamine (22.4 nmol/mg protein) and uridine-5'-diphospho-N-acetylglucosamine (7.4 nmol/mg protein).

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:498927 CAPLUS  
 DOCUMENT NUMBER: 99:98927  
 ORIGINAL REFERENCE NO.: 99:15104h,15105a  
 TITLE: Combined action of acivicin and D-galactosamine on pyrimidine nucleotide metabolism in hepatoma cells  
 AUTHOR(S): Leube, Karen; Keppler, Dietrich O. R.  
 CORPORATE SOURCE: Biochem. Inst., Univ. Freiburg, Freiburg/Br., D-7800, Fed. Rep. Ger.  
 SOURCE: Biochemical Pharmacology (1983), 32(12), 1865-9  
 CODEN: BCPA6; ISSN: 0006-2952  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB The glutamine antagonist acivicin (I) [42228-92-2] strongly reduced CTP [65-47-4] and GTP [86-01-1] contents in AS-30D rat hepatoma cells in suspension. UTP [63-39-8] had fallen to only 63% of the resp. control after 4 h; however, by combining acivicin with the uridylate-trapping sugar analog D-galactosamine [7535-00-4], a synergistic decrease in UTP contents to 7% of control was induced. Incorporation of  $^{14}\text{C}$  into purine and pyrimidine nucleotides, determined by radio-high performance liquid

chromatog., showed marked inhibition of purine and pyrimidine biosynthesis de novo; the latter was reduced to 35% of control. The inhibitory potency of acivicin on glutamine-dependent carbamoylphosphate synthetase and consequently on de novo uracil nucleotide formation was also reflected by the complete suppression of the D-galactosamine-induced rise in total uridylate. Induction of UTP deficiency by interference with the 1st and rate-limiting step in pyrimidine biosynthesis de novo, together with trapping of uridylate by D-galactosamine, may provide a promising approach to the chemotherapy of hepatocellular carcinoma.

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:557834 CAPLUS

DOCUMENT NUMBER: 83:157834

ORIGINAL REFERENCE NO.: 83:24711a,24714a

TITLE: Effect of D-glucosamine and D-galactosamine on the uridine nucleotide concentration in mouse myeloid tumor (Graffi) and myeloma MOPC-21

AUTHOR(S): Chelibonova-Lorer, Kh.

CORPORATE SOURCE: Inst. Gen. Comp. Pathol., Sofia, Bulg.

SOURCE: Neoplasma (1975), 22(1), 23-7  
CODEN: NEOLA4; ISSN: 0028-2685

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effect of D-glucosamine [3416-24-8] and D-galactosamine [7535-00-4] on the content of uridine nucleotides in myeloid tumor (Graffi) and myeloma MOPC-21 of mice was investigated in vivo. After treatment with aminosugars (1.5g/kg., i.p.) a marked decrease in UTP [63-39-8] and UDP-glucose [133-89-1] quantity was found. The trapping of uridine phosphates by formation of UDP-sugar derivs. was different in the 2 tumors and depended on the aminosugar employed. D-glucosamine provoked an increase in the UDP-N-acetylglucosamine [528-04-1] pool size in myeloid tumor (Graffi) and myeloma MOPC-21. D-Galactosamine administration led to formation of UDP-galactosamine [17479-06-0] and UDP-N-acetylglucosamine in myeloma MOPC-21, while in myeloid tumor (Graffi) an increase in the content of UDP-N-acetylglucosamine was obtained only.

=> d his

(FILE 'HOME' ENTERED AT 08:01:15 ON 22 AUG 2008)

FILE 'REGISTRY' ENTERED AT 08:01:26 ON 22 AUG 2008

E "UDP GALACTOSAMINE"/CN 25

E "UDP-GALACTOSAMINE"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 08:02:31 ON 22 AUG 2008

L2 38 S L1

L3 22 S L2 NOT PY>2003

L4 26 S L1/BIOL

L5 15 S L4 NOT PY>2002

FILE 'REGISTRY' ENTERED AT 08:12:22 ON 22 AUG 2008

FILE 'CAPLUS' ENTERED AT 08:12:22 ON 22 AUG 2008

L6 3 S L5 AND (CANCER? OR TUMOR? OR NEOPLAS?)

=> s 15 and biotin

35026 BIOTIN

127 BIOTINS

35039 BIOTIN

(BIOTIN OR BIOTINS)  
L7 0 L5 AND BIOTIN

=> s 12 and biotin  
35026 BIOTIN  
127 BIOTINS  
35039 BIOTIN

(BIOTIN OR BIOTINS)  
L8 0 L2 AND BIOTIN

=> s 14 not py>2003  
6143104 PY>2003

L9 15 L4 NOT PY>2003

=> s 11/thu  
38 L1  
1040588 THU/RL  
L10 1 L1/THU  
(L1 (L) THU/RL)

=> d ibib abs

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:1293546 CAPLUS  
DOCUMENT NUMBER: 144:40813  
TITLE: Selectively treating cancer and angiogenesis  
associated diseases with specific glycosaminoglycan  
polymers  
INVENTOR(S): Deangelis, Paul L.  
PATENT ASSIGNEE(S): Board of Regents of University of Oklahoma, USA  
SOURCE: U.S. Pat. Appl. Publ., 92 pp., Cont.-in-part of U.S.  
Ser. No. 542,248.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 29  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20050272696	A1	20051208	US 2005-172145	20050630
EP 1832662	A2	20070912	EP 2007-7453	19990401
EP 1832662	A3	20071107		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, MK, RO, SI				
US 6444447	B1	20020903	US 1999-437277	19991110
US 20030104601	A1	20030605	US 2001-842484	20010425
US 20030099967	A1	20030529	US 2002-142143	20020508
US 7307159	B2	20071211		
US 20060188966	A1	20060824	US 2002-195908	20020715
US 20030113845	A1	20030619	US 2002-217613	20020812
US 6987023	B2	20060117		
US 20040132143	A1	20040708	US 2003-642248	20030815
US 7223571	B2	20070529		
US 20050059118	A1	20050317	US 2004-990844	20041117
US 20050266460	A1	20051201	US 2005-124215	20050509
US 7232684	B2	20070619		
AU 2005287397	A1	20060330	AU 2005-287397	20050630
CA 2572154	A1	20060330	CA 2005-2572154	20050630
WO 2006033693	A2	20060330	WO 2005-US23452	20050630
WO 2006033693	A3	20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1768678	A2	20070404	EP 2005-788952	20050630
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
US 20060141535	A1	20060629	US 2006-352664	20060213
US 20070298461	A1	20071227	US 2007-799130	20070501
US 20080125393	A1	20080529	US 2007-977131	20071023
PRIORITY APPLN. INFO.:			US 1998-80414P	P 19980402
			US 1998-107929P	P 19981111
			US 1999-283402	B2 19990401
			US 1999-437277	A2 19991110
			US 2000-199538P	P 20000425
			US 2001-842484	A2 20010425
			US 2001-289554P	P 20010508
			US 2002-142143	A2 20020508
			US 2002-195908	A2 20020715
			US 2002-404356P	P 20020816
			US 2003-479432P	P 20030618
			US 2003-491362P	P 20030731
			US 2003-642248	A2 20030815
			US 2004-584442P	P 20040630
			US 1998-178851	A 19981026
			EP 1999-917339	A3 19990401
			US 2000-245320P	P 20001102
			US 2001-842930	A3 20010425
			US 2001-296386P	P 20010606
			US 2001-303691P	P 20010706
			US 2001-305263P	P 20010713
			US 2001-313258P	P 20010817
			US 2001-345497P	P 20011109
			US 2002-350642P	P 20020122
			US 2002-391787P	P 20020620
			US 2002-217613	A1 20020812
			US 2004-990844	A3 20041117
			US 2005-124215	A1 20050509
			US 2005-172145	A 20050630
			WO 2005-US23452	W 20050630

AB The present invention demonstrates that defined, specific GAG mols. have discerned differential effects, and that different types of cancers are prevented from proliferating and/or killed by oligosaccharides of different sizes; one size sugar does not treat all cancers effectively. Likewise, certain size GAGs have more potent angiogenic properties; thus, mixts. of different sizes of GAG mols. are not optimal. Therefore, the present invention is directed to methods of "personalized medicine", in which customized defined, specific GAG mols. are administered to a patient, wherein the defined, specific GAG mols. are chosen based on the specific ailment from which the patient is suffering and/or the response of in vitro testing of the ability of the defined, specific GAG mols. to treat, inhibit and/or prevent the ailment in a sample from the patient.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	33.20	54.62
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 08:20:33 ON 22 AUG 2008